133 related articles for article (PubMed ID: 29493549)
21. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis.
Pinover WH; Hanlon A; Lee WR; Kaplan EJ; Hanks GE
Cancer; 1996 Apr; 77(7):1334-41. PubMed ID: 8608512
[TBL] [Abstract][Full Text] [Related]
22. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
Reggiani Bonetti L; Lionti S; Domati F; Barresi V
World J Gastroenterol; 2017 Feb; 23(8):1412-1423. PubMed ID: 28293088
[TBL] [Abstract][Full Text] [Related]
23. Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis.
He X; Wu W; Lin Z; Ding Y; Si J; Sun LM
Gastric Cancer; 2018 May; 21(3):391-400. PubMed ID: 29052053
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer.
Mittendorf EA; Ballman KV; McCall LM; Yi M; Sahin AA; Bedrosian I; Hansen N; Gabram S; Hurd T; Giuliano AE; Hunt KK
J Clin Oncol; 2015 Apr; 33(10):1119-27. PubMed ID: 25488970
[TBL] [Abstract][Full Text] [Related]
25. Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
Tsumura H; Ishiyama H; Tabata KI; Katsumata H; Kobayashi M; Ikeda M; Kurosaka S; Fujita T; Kitano M; Satoh T; Yanagisawa N; Hayakawa K; Iwamura M
Prostate; 2017 Nov; 77(15):1520-1527. PubMed ID: 28905446
[TBL] [Abstract][Full Text] [Related]
26. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
27. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Bhindi B; Karnes RJ; Rangel LJ; Mason RJ; Gettman MT; Frank I; Tollefson MK; Lin DW; Thompson RH; Boorjian SA
J Urol; 2017 Dec; 198(6):1286-1294. PubMed ID: 28669765
[TBL] [Abstract][Full Text] [Related]
28. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
29. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
30. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
31. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.
Chen YT; Huang ZP; Zhou ZW; He MM
Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526
[TBL] [Abstract][Full Text] [Related]
32. ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.
Shah RB; Li J; Dhanani N; Mendrinos S
Urol Oncol; 2016 Mar; 34(3):120.e1-7. PubMed ID: 26585946
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy and Male Breast Cancer: A Population-based Registry Analysis.
Madden NA; Macdonald OK; Call JA; Schomas DA; Lee CM; Patel S
Am J Clin Oncol; 2016 Oct; 39(5):458-62. PubMed ID: 24781343
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
35. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.
Leapman MS; Cowan JE; Simko J; Roberge G; Stohr BA; Carroll PR; Cooperberg MR
Eur Urol; 2017 May; 71(5):750-759. PubMed ID: 27940155
[TBL] [Abstract][Full Text] [Related]
36. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
37. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision.
Dikken JL; Coit DG; Klimstra DS; Rizk NP; van Grieken N; Ilson D; Tang LH
Cancer; 2012 Jan; 118(2):349-57. PubMed ID: 21720993
[TBL] [Abstract][Full Text] [Related]
38. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
40. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
